Return to Listing

1 result(s) for Tarceva

PI Name Protocol # Title
Khaled Tolba IRB00011671 TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080